

**Complete Listing of Claims Pursuant to 37 C.F.R. §1.121**

Pursuant to 37 C.F.R. §1.121 the following is a complete listing of the claims of the present application. In this set of claims, please amend the claims as follows. The following listing of claims will replace all prior versions of claims in the application:

**Listing of the Claims:**

1.-36. (canceled)

37. (currently amended) An immunogenic composition characterized by the ability to generate an antibody which distinguishes between phosphorylated and dephosphorylated tau comprising:

(a) a peptide consisting essentially of a tau amino acid sequence Lys-Ile-Gly-Ser-Thr-Glu-Asn-Leu-Lys (residues 259-267 in SEQ ID NO:1) conjugated to

(b) a carrier molecule, wherein the carrier molecule induces or enhances an immune response to the peptide of (a).

38-41. (canceled)

42. (previously presented) The immunogenic composition of claim 37, wherein the Ser (residue 262 of SEQ ID NO:1) is phosphorylated.

43. (canceled).

44. (currently amended) A method of producing an antibody ~~to a tau peptide~~ which distinguishes between phosphorylated and dephosphorylated tau, the method comprising administering to an animal an antibody-producing amount of an immunogenic composition comprising:

(a) a peptide consisting essentially of a tau amino acid sequence Lys-Ile-Gly-Ser-Thr-Glu-Asn-Leu-Lys (residues 259-267 in SEQ ID NO:1) conjugated to

(b) a carrier molecule, wherein the carrier molecule induces or enhances an immune response to the peptide of (a).

45-48. (canceled)

49. (previously presented) The method of claim 44, wherein the Ser (residue 262 of SEQ ID NO:1) is phosphorylated.

50. (canceled)